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Abstract
Warfarin, the standard oral anticoagulant drug used in Ireland, is a widely prescribed medication, particularly in the
elderly. A HSE Mid-Western Area wide audit was undertaken over a 12-month period to examine the prevalence and
indications for warfarin use and haemorrhagic complications associated with the drug. Every patient receiving warfarin
therapy over a 13-week period was included (2564). The age standardised rate varied from 0.09% of 35-39 year olds to
6.1% of 80-84 year olds. Atrial fibrillation was the most common indication (54% ) in patients attending the
Mid-Western Regional Hospital anticoagulation clinic. The annual cumulative incidence of adverse haemorrhagic events
in patients with a recorded INR=5.0 episode was 16.6%. The incidence of major and minor haemorrhagic events per
INR=5.0 episode was 1.3% and 15.3% respectively. The most common sites of haemorrhage were genitourinary (39%) and
gastrointestinal (27%). No fatal or intracranial haemorrhage relating to episodes of over-anticoagulation were
reported during the audit period. The most frequent reason for over-anticoagulation was drug interaction (43%). In 74%
of patients, the elevated INR was reversed by omitting or reducing warfarin dose. In 17% of cases, vitamin K was
administered. Only 3% of incidents were treated with fresh frozen plasma or prothrombin complex concentrates.
Introduction
Warfarin is effective in the prevention of venous thromboembolism, thromboses in patients with heart valve prostheses,
embolic stroke in patients with chronic atrial fibrillation and cerebrovascular disease. It is also of proven benefit
in patients with pulmonary embolism and as secondary prophylaxis after myocardial infarction.1, 2 Nonetheless, warfarin
is associated with a significant incidence of serious haemorrhage. In a review of observational studies, average
annual rates of fatal, major and major/minor haemorrhages were 0.8, 4.9 and 15% respectively.3
The incidence of haemorrhage in warfarinised patients is directly related to the adequacy of control. Systems for the
control of warfarin are evolving and becoming more sophisticated. Quality improvements in systems include the
increasing use of computerised dosing, specialist nursing input into monitoring patients and the use of near patient
testing for selected patients. These have been initiated with set protocols recommended by the British Committee for
Standards in Haematology.4, 5
The delivery of care to warfarinised patients in the HSE Mid-Western area has undergone major changes between 1999 and
2002. During this time a computerised nurse led anticoagulation clinic replaced the more traditional physician led
system. This was achieved with cross-disciplinary co-operation and resources from the HSE Mid-Western area and the
national partnership process. The audit was undertaken after this period of change.
This audit aimed to establish the age related incidence of warfarin use in the HSE Mid-Western area and determine the
frequency of indications for its use. Causes of over-anticoagulation were examined which we hope will aid clinicians
in the future management of warfarin patients. With increasing worries about prion-transmitted (nvCJD) infection,
examination of the practice of transfusing fresh frozen plasma to reverse over-anticoagulated patients has gained in
importance. We also audited the use of blood products, vitamin K and stopping warfarin as means of reversal of
over-anticoagulated patients.
Methods
Identification of warfarinised patients (laboratory computer records)
To quantify patients on warfarin within the borders of the HSE Mid-Western area, hospital laboratory computer records
were interrogated in its laboratories, i.e. Mid-Western Regional Hospital Limerick, St Johnâs Hospital Limerick,
Ennis and Nenagh General Hospitals. We achieved this through COGNOS, a data extracting software package for iLAB, the
laboratory information system. This number was quantified from a 13-week period, August 1st 2002 to October 31st 2002,
a timeframe we deemed to be the maximum review interval for a patient on warfarin. Patients who had an INRe1.5 on 4
occasions over 2 weeks or more were deemed to be on warfarin unless there was a defined exclusion. For example, a
patient known to have an elevated INR secondary to other causes, e.g. hereditary bleeding disorders, disseminated
intravascular coagulation (DIC) or liver abnormalities were excluded. To ensure completeness of the computerised
record and to allow the denominator of the population of the HSE Mid-Western area to be accurately utilised,
laboratories on the borders of the HSE Mid-Western Area (Tralee, Clonmel, Cashel, Galway, Mallow and Waterford) were
contacted. This allowed us to establish whether any patients, with Mid-Western Area addresses, had their INR monitored
outside our region. Patients whose INR was monitored exclusively by near patient testing (Coagucheck) were determined
by liaison with Roche Diagnostics and their customers. The resulting data was analysed and age standardised (Irish
population standard) using the direct method.
Identification of over-anticoagulated patients (laboratory computer records)
Over-anticoagulated patients were quantified from August 1st 2002 to August 1st 2003. Patients with an INR=5.0 episode
in the 12-month audit period were identified from computer records using COGNOS, in HSE Mid-Western area hospital
laboratories, to determine the incidence and extent of haemorrhages in such instances. An INR of five or above was
chosen because INR values greater than five have shown a consistent increase in haemorrhagic events.6, 7
Investigation of over-anticoagulated patients and categorisation of associated haemorrhagic events
Patients with INRs=5.0 were linked to accident and emergency attendances or inpatient/clinic records. Anticoagulation
nurses and haematology medical staff examined the casualty record and hospital chart. We examined the record to
determine the suspected primary cause of loss of INR control, action taken for its reversal and if any blood loss was
evident relating to the episode of over-anticoagulation. General practitioner surgeries or nursing homes within the
HSE Mid-Western Area, in care of patients who presented with an INR=5.0, were supplied with a questionnaire for each
patient to obtain more information about the over-anticoagulation incident. Haemorrhages were categorised as major if
they were fatal, intracranial, retroperitoneal or lead to a drop in haemoglobin concentration of 4g/dl or more and/or
required transfusion of a minimum of 2 units of blood. Minor haemorrhages were all cases of haemorrhage not classified
as major.
Results
The number of patients estimated to be receiving warfarin within the HSE Mid-Western area was 2564. As expected, the
age standardised rates (Table 1) rose sharply with age and in-patient age range of 80-84 it reached a maximum of 6.1%
of this population (61/1000 standardised to Irish census 2002). In the very elderly (>85 years), the rate declined to
3.6% (36.5/1000).
Table 1 Age standardized prevalence rates of war farin use in the HSE Mid-Western Area
Age
group
Number on
warfarin
HSE Mid-West area
population
Ireland population
figures
Age specific rates per 1000 people
mid-west
15-19 3 27936 313188 0.1
20-24 12 28048 328334 0.42
25-29 6 24914 312693 0.24
30-34 30 24839 304676 0.86
35-39 23 24530 290906 0.94
40-44 49 23387 271984 2.1
45-49 54 22085 249604 2.4
50-54 127 20892 230843 6.1
55-59 203 17771 197294 11.4
60-64 278 13728 154252 20.3
65-69 391 12024 133474 32.5
70-74 428 10080 112129 42.5
75-79 493 8338 89815 59.1
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80-84 323 5295 58857 61.0
85+ 137 3756 41726 36.5
Total 2557 229591 3917203
Overall age standardized rate 7.2/1000
Reasons for warfarin therapy in patients attending the Mid-Western Regional Hospital clinic are summarised in Table 2.
The most common indication for treatment was atrial fibrillation (54%). The ratio of male to female patients was
1.4:1. The average age of the patient was 66.5 years.
Table 2 Frequency of indications for warfarin therapy in the Mid-Western Regional Hospital Limerick clinic
Indication n % of total cases
Atrial Fibrillation 404 54.4
Pulmonary Embolism/ Deep Vein Thrombosis 135 18.2
Mechanical Prosthetic Valve Replacement 86 11.6
Post-operative Primary Prevention of DVT 37 5.0
Cerebrovascular Disease ¥ 36 4.8
Cardiac Disease ´° 30 4.0
Peripheral Vascular Disease 10 1.4
More than 1 of the above recorded 5 <1.0
Total 743 100
¥ - Denotes CVA/Transient Ischaemic Attacks
´° - Denotes Cardiomyopathies/Ischaemic Heart Disease/Congenital Heart Disease/Prevention of Myocardial Infarction
The number of patients presenting with INR=5.0 episodes in the 12-month audit period was 463. Detailed information was
available on 327 of these episodes from which confirmation of wafarinisation was made in 307 cases. Information on
remaining 136 episodes was unavailable due to missing/non-documentation of over-anticoagulation events and the
inability to access some community or general practitioner records.
Table 3 Suspected cause of over-anticoagulation in patients with INRs=5.0
Suspected primary cause of INR=5.0 n % of total cases
Interacting medication 133 43.3
Accidental overdose 42 13.6
Overdose at Warfarin induction 30 9.9
Alcohol related 27 8.8
Prescription error 12 3.9
Hepatic dysfunction 8 2.6
Pre-analytical error 8 2.6
Malnutrition/Malabsorption of Vitamin K 3 1.0
Unknown 44 14.3
Total 307 100.0
Table 3 shows the suspected primary cause of INR=5.0 cases, the most common being drug interaction (43%).
Within the audit period, 51 patients (16.6%) who presented with an INR=5.0 experienced episodes of haemorrhage. Of
these 47 (15.3%) had a minor haemorrhage while 4 (1.3%) had a major haemorrhage. No fatal haemorrhage relating to
over-anticoagulated patients was reported during the audit period. The most common sites of haemorrhage were
genitourinary (39.2%) and gastrointestinal (27.5%). Other types of haemorrhages discovered in over-anticoagulated
patients were bruising/haematoma of soft tissue (11.8%), epistaxis (7.8%), haemoptysis (5.9%), gingival/oral mucosal
(3.9%) and other sites (3.9%). While this audit focused on episodes of haemorrhage, it was also noted that in the
12-month audit period, only one of the 932 Mid-Western Regional Hospital anticoagulation clinic patients presented
with a thromboembolism while on warfarin.
Table 4 Action taken by anticoagulation staff to reverse over- anticoagulation
Action taken to counteract INRs=5.0 n % of total cases
Warfarin dose omitted/reduced only 227 74.0
Vitamin K (Oral/IV) 53 17.3
Fresh Frozen Plasma (FFP) 7 2.3
Prothrombin Complex Concentrate (PCC) 3 1.0
Warfarin therapy terminated 9 2.9
None 8 2.6
Total 307 100
Table 4 details the action taken to counteract episodes of over-anticoagulation. The most frequently used method of
INR reversal was warfarin dose omission/reduction.
Information not available on 7 patients whose INR was tested in laboratories outside the borders of the HSE-Western
area.
No patients on warfarin between the ages of 0-14 were detected during the study period.
This table shows the number of patients on warfarin in different age groups. Column 4 shows the Irish figures from the
census data for this age group and the last line of column four contains the total population figures. The rates in
column 5 show the age specific rates in the Mid-West standardized against the Irish population to allow easy
comparison with other areas.
Discussion
Notable features from the audit included the calculation of age specific rates for warfarin patients in the
Mid-Western area. Changes in the indications for anticoagulation have resulted in a progressive increase in patients
requiring lifelong oral anticoagulant therapy, especially in the older age groups. The number of patients on oral
anticoagulants has increased rapidly over the past five years, principally due to the large number of elderly patients
with chronic atrial fibrillation commenced on this therapy for the prevention of stroke. This audit confirmed this
with over half of patients (54%) attending the warfarin clinic with atrial fibrillation as their primary indication
for treatment.
This audit also highlights the encouraging and predominant use of warfarin dose omission/reduction (74%) to counteract
over-anticoagulated patients in accordance with hospital and British Committee for Standards in Haematology (BCSH)
guidelines. Only 17% of over-anticoagulated patients were administered vitamin K. With increasing concern regarding
transfusion-transmitted infection and prion disease, the use of fresh frozen plasma in only 7 and prothrombin complex
concentrate in only 3 out of 307 patients is also encouraging. BCSH guidelines suggest that factor concentrates are
more effective than frozen plasma (Octoplas) in the treatment of over-anticoagulation. Recent trends in the
Mid-Western Regional Hospital confirm that prothrombin complex concentrate is now the preferred option for serious
haemorrhage in over-anticoagulated patients where immediate correction is needed.8 It is issued after discussion with
the consultant haematologist on-call who advises on appropriate correction of elevated INR.
Due to its narrow therapeutic index and its pharmacokinetic and pharmacodynamic properties, warfarin is highly
susceptible to interactions with other drug components. The high incidence of interacting medication (43%) as a cause
of loss of INR control needs to be addressed. The most common clinical picture associated with drug induced
alterations in INR was the treatment of exacerbations of chronic obstructive pulmonary disease and infections.
Antibiotics and antibiotic/steroid combinations were the most common category of interacting drugs. When prescribing
new medications, ideally a non-interacting drug should be chosen. Where this is not possible, more frequent INR
monitoring and dose alteration is necessary until the course of medication is completed or warfarin control has
stabilised. This is routinely encouraged in the warfarin clinic.
Prescription and pre-analytical errors resulting in an elevated INR are amenable to reduction in the future. A typical
example of a prescription error included clerical errors in dosage charts of in-patients resulting in overdosing,
although some cases involved unexplained dosage increase by medical staff with the INR within therapeutic range. Three
cases of minor haemorrhage were associated with prescription errors. Pre-analytical errors primarily involved
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inappropriate methods of specimen collection. An example of these errors would include a specimen taken from a patient
intravenous line resulting in dilution of patient plasma giving a falsely elevated INR. No episodes of haemorrhage
were reported with these types of errors.
Initiating warfarin therapy is undoubtedly one of the most difficult aspects of warfarin management. As well as the
frequent elderly age of the patient, the physician may encounter a previously unknown bleeding risk, sensitivity, or
resistance to oral anticoagulant effects. One common pitfall is the unnecessary urgency to achieve a therapeutic INR
for chronic conditions such as atrial fibrillation. A previous audit of the start of anticoagulant treatment reported
that 58% of INR results were not therapeutic upon patient discharge.9
Most hospitals or surgeries initiate warfarin with high loading doses, most often ten milligrams on days one and two
of therapy. This audit discovered 30 cases (9.9%) of INRs=5.0 with 1 associated minor haemorrhage event due to
overdose at induction, thereby confirming this as a significant cause of over-anticoagulation. Multiple studies have
confirmed the fallacy of relying on a high loading dose, which can potentially result in early over-anticoagulation
and the development of a potential hypercoagulable state. It has been demonstrated that a 10-mg loading dose is
unlikely to be more effective than a 5-mg dose in achieving a therapeutic INR by day 4 or 5 of therapy.10, 11
The annual incidence of major (1.3%) and minor (15.3%) haemorrhages per INR =5.0 episode appears to be broadly in line
(allowing for differences in definition) with large clinic population studies showing major haemorrhage rates of 2%
and minor haemorrhage rates of just over 5%.12 Comparison is difficult because the criteria for defining the severity
of bleeding vary considerably between studies, accounting in part for the variation in the rates of bleeding. We
acknowledge the limitations in using INR=5.0 in calculating the incidence of haemorrhages, including the fact that
patients experiencing haemorrhage within INR range or less than 5.0 were not systematically identified. In addition,
most intracranial haemorrhages occur with INR within therapeutic range.13 However, during the audit period, no fatal or
intracranial haemorrhage in warfarinised patients (with any INR range) was reported. Of the 932 patients attending the
MWRH clinic in the 12-month audit period, only one experienced a thromboembolic event. This patient was within INR
therapeutic range at the time of the embolus being diagnosed.
There is a continuous need to monitor the standards of anticoagulation achieved and the quality of service delivered.
The age standardised rates in this study allow more detailed service delivery planning which clearly needs to be
targeted to the needs of the elderly population. The information in this audit may be useful to other HSE areas within
Ireland to assist with benchmarking and service planning.
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